Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Typhoid Fever Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Typhoid Fever Overview | 8 | 1 |
| Pipeline Products for Typhoid Fever Comparative Analysis | 9 | 1 |
| Typhoid Fever Therapeutics under Development by Companies | 10 | 1 |
| Typhoid Fever Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Typhoid Fever Pipeline Products Glance | 12 | 4 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Unknown Stage Products | 15 | 1 |
| Typhoid Fever Products under Development by Companies | 16 | 1 |
| Typhoid Fever Products under Investigation by Universities/Institutes | 17 | 1 |
| Typhoid Fever Companies Involved in Therapeutics Development | 18 | 9 |
| GlaxoSmithKline Plc | 18 | 1 |
| Indian Immunologicals Limited | 19 | 1 |
| Nanotherapeutics, Inc. | 20 | 1 |
| Prokarium Limited | 21 | 1 |
| Protein Potential, LLC | 22 | 1 |
| Sanofi Pasteur SA | 23 | 1 |
| Shantha Biotechnics Limited | 24 | 1 |
| SK Chemicals Co., Ltd. | 25 | 1 |
| Zydus Cadila Healthcare Limited | 26 | 1 |
| Typhoid Fever Therapeutics Assessment | 27 | 8 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Combination Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 13 |
| (paratyphoid (bivalent) + typhoid) vaccine Drug Profile | 35 | 1 |
| (paratyphoid + typhoid) vaccine Drug Profile | 36 | 1 |
| (shigella + typhoid) vaccine Drug Profile | 37 | 1 |
| (Streptococcal pneumonia + typhoid) vaccine Drug Profile | 38 | 1 |
| Typhella Drug Profile | 39 | 2 |
| Typhetec Drug Profile | 41 | 1 |
| typhoid vaccine Drug Profile | 42 | 1 |
| typhoid vaccine Drug Profile | 43 | 1 |
| typhoid vaccine Drug Profile | 44 | 1 |
| typhoid vaccine Drug Profile | 45 | 1 |
| typhoid Vi polysaccharide [strain S typhi Ty2] vaccine Drug Profile | 46 | 1 |
| ViCRM-197 Drug Profile | 47 | 1 |
| Typhoid Fever Dormant Projects | 48 | 1 |
| Typhoid Fever Discontinued Products | 49 | 1 |
| Typhoid Fever Product Development Milestones | 50 | 4 |
| Featured News &Press Releases | 50 | 1 |
| Mar 11, 2013: Prokarium And University Of Birmingham Receive 0.4m Grant To Develop Next Generation Vaccines | 50 | 1 |
| Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine | 50 | 1 |
| Jun 23, 2011: Sanofi Pasteur s Typhim Vi Receives Prequalification From World Health Organization | 50 | 1 |
| Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate | 51 | 1 |
| Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine | 51 | 1 |
| Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine | 52 | 1 |
| Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study | 52 | 1 |
| Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |